Metastatic bone disease: Clinical features, pathophysiology and treatment strategies

Cancer Treatment Reviews

Volumn 27, Issue 3, 2001, Pages 165-176

  Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANALGESIC AGENT; ANASTROZOLE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; ETIDRONIC ACID; EXAMESTANE; GONADORELIN; GONADORELIN DERIVATIVE; IBANDRONIC ACID; LETROZOLE; LEXIDRONAM SAMARIUM SM 153; MEGESTROL ACETATE; PAMIDRONIC ACID; STRONTIUM 89; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BEAM THERAPY; BONE CELL; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CELL; CANCER PAIN; CANCER PATIENT; CANCER RESEARCH; CELL ACTIVITY; CELL INTERACTION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG RESEARCH; EARLY CANCER; FRACTURE; HORMONAL THERAPY; HUMAN; HYPERCALCEMIA; IN VITRO STUDY; MULTIPLE MYELOMA; OSTEOCLAST; OSTEOPOROSIS; PATHOPHYSIOLOGY; PROSTATE CANCER; QUALITY OF LIFE; SPINAL CORD COMPRESSION; STEM CELL TRANSPLANTATION; SYMPTOM; TARGET CELL;

EID: 0035010803     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2000.0210     Document Type: Article

References (53)

1. Rubens, R. D. Coleman, R. E. Bone metastases. Abeloff, M, DArmitage, J, OLichter, A, SNiederhuber, J, E, Clinical Oncology, Churchill, New York: Livingstone, 2000, 836, 871.
2. Batson O. V. The role of the vertebral veins in the metastatic process. Ann Intern Med. 16:1942;38.
3. Urwin G. H., Percival R. C., Harris S., Kanis J. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol. 57:1985;721.
4. Coleman R. E. Biochemical markers of malignant bone disease. Rubens RD, Mundy GR eds Cancer and the Skeleton. 2000;Martin Dunitz, London. p. 137-150.
5. Yoneda T., Michigami T., Yi B. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treat Rev. 25:1999;293-299.
6. van der Pluijm G., Lowik C., Papapoulos S. Tumour progression and angiogenesis in bone metastases from breast cancer: new approaches to an old problem. Cancer Treat Rev. 26:2000;11-27.
7. Eisenberger M. A., Crawford E. D., Wolf M. Prognostic factors in stage D2 prostate cancer: important implications for future trials: results of a Co-operative Intergroup Study (INT 0036). Semin Oncol. 21:1994;613-619.
8. Kyle R. A., Blade J. Multiple myeloma and related disorders. Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE eds, Clinical Oncology, 2nd edn. 2000;Churchill Livingstone, New York. p. 2597-2619.
9. Coleman R. E., Rubens R. D. Clinical course and prognostic factors following recurrence from breast cancer. Br J Cancer. 17:1998;336-340.
10. Coleman R. E., Rubens R. D. The clinical course of bone metastases from breast cancer. Br J Cancer. 55:1987;61-66.
11. O'Reilly S., Richards M. A., Rubens R. D. Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer. 26:1990;574-577.
12. Robson M., Dawson N. How is androgen dependent metastatic prostate cancer best treated? Haematol Oncol Clinics North Am. 10:1996;727-747.
13. Bataille R., Boccadoro M., Klein B. C-reactive protein and 2 microglobulin produce a simple and powerful myeloma staging system. Blood. 80:1992;733.
14. Kanis J. A., McCloskey E. V. Bisphosphonates in the treatment of multiple myeloma. Body J. J. Tumour bone diseases and osteoporosis in cancer patients. 2000;457-482 Marcel Dekker Inc, New York; USA.
15. Morton A. R., Lipton A. Hypercalcaemia. Abeloff M D, Armitage J O, Lichter A S, Niederhuber J E. Clinical Oncology. 2000;719-735 Churchill Livingstone, New York.
16. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathological fracture. Clin Orthop Rel Res. 249:1989;256-264.
17. Rodichok L. D., Ruckdeschel J. C., Harper G. R. Early detection of spinal epidural metastases: the role of myelography. Ann Neurol. 20:1986;696.
18. Harrington K. D. Spinal stabilisation. Rubens RD, Mundy GR eds, Cancer and the Skeleton. 2000;Martin Dunitz, London. p. 245-262.
19. Janjan N. A. Radiation of bone metastases: conventional techniques and the role of systemic radiopharmaceuticals. Cancer. 80:1997;1628-1645.
20. 89in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 27:1991;954-958.
21. 89in prostatic and breast cancer patients. Semin Oncol. 20:1993;44-48.
22. 153Sm-Ethylenediaminetetramethylenephosphate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 33:1997;1583-1591.
23. Rogers M. J., Xiong X., Ji X. Inhibition of growth of Dictyostelium discoideum amoeboe by bisphosphonates is dependent on cellular uptake. Pharmacol Res. 14:1997;625-630.
24. Jagdev S. P., Coleman R. E., Shipman C. M., Amin Rostami-H., Croucher P. I. The bishosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001.
25. Rogers M. J., Watts D. J., Russell R. G. G. Overview of bisphosphonates. Cancer. 80:1997;1652-1660.
26. Body J. J., Coleman R. E., Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 22:1996;265-287.
27. Purohit O. P., Anthony C., Radstone C. R., Owen J., Coleman R. E. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer. 70:1994;554-558.
28. Ernst D. S., Brasher P., Hagen N. A randomised controlled trial of intravenous clodronate in metastatic bone disease and pain. J Pain Symptom Manag. 13:1997;319-332.
29. Body J. J., Lichinitser M. R., Diehl I. E. Double-blind placebo controlled trial of ibandronate in breast cancer metastatic to bone. Proc ASCO. 18:1999;575a.
30. Berenson J. R., Lipton A., Rosen L. S. Phase I clinical study of a new bisphosphonate, zoledronate (CGP-42446), in patients with osteolytic bone metastases. Blood. 88:1998;586a.
31. Vinholes J. J., Purohit O. P., Abbey M. E., Eastell R., Coleman RE. Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol. 8:1997;1243-1250.
32. Body J. J., Bartl R., Burckhardt P. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol. 16:1998;3890-3899.
33. Paterson A. H. G., Powles T. J., Kanis J. A., McCloskey E., Hanson J., Ashley S. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11:1993;59-65.
34. Lahtinen R., Laakso M., Palva I., Virkkunen P. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet. 340:1992;1049-1052.
35. McCloskey E. V., Maclennan I. C. M., Drayson M., Chapman C., Dunn J., Kanis J. A. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol. 100:1998;317-325.
36. Hultborn R., Ryden S., Gunderson S., Holmberg E., Wallgren U-B. Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial. Acta Oncologica. 35:1996;73-74.
37. Conte P. F., Mauriac L., Calabresi F. Delay in progression of bone metastases treated with intravenous pamidronate: results from a multicentre randomised controlled trial. J Clin Oncol. 14:1996;2552-2559.
38. Theriault R. L., Lipton A., Hortobagyi G. N. Pamidronate reduces skeletal morbidity in women with advance breast cancer and lytic bone lesions: a randomised, placebo- controlled trial. J Clin Oncol. 17:1999;846-854.
39. Hortobagyi G. N., Theriault R. L., Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 335:1996;1785-1791.
40. Berenson J. R., Lichtenstein A., Porter L. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 334:1996;488-493.
41. Hortobagyi G. N., Theriault R. L., Lipton A. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 16:1998;2038-2044.
42. Lipton A., Demers L., Curley E. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 34:1998;2021-2026.
43. Berenson J. R., Lichtenstein A., Porter L. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 16:1998;593-602.
44. Smith J. R. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 141:1989;85-87.
45. Body J. J., Lortholary A., Romieu G., Vigneron A. M., Ford J. A dose-finding study of zoledronate in hypercalcaemic cancer patients. J Bone Miner Res. 14:1999;1557-1661.
46. Coleman R. E., Purohit O. P., Black C. Double-blind, randomised, placebo-controlled study of oral ibandronate in patients with metastatic bone disease. Ann Oncol. 10:1999;311-316.
47. Saarto S., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: a randomised study in premenopausal patients. J Clin Oncol. 15:1997;1341-1347.
48. Powles T. J., Paterson A. H. G., Nevantaus A. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. ASCO Proc. 17:1998;468a.
49. Diel I., Solomayer E-F. Goerner R et al. Adjuvant treatment of breast cancer patients with the bisphosphonate clodronate reduces incidence and number of bone and non-bone meta stases. ASCO Proc. 16:1997;130a.
50. Saarto, T. Blomqvist, C. Virkkunen, P. Elomaa, I. Adjuvant clodronate treatment does not reduce the frequency of skeletla metastases in node-positive breast cancer patients: 5 year results of a randomised conrolled trial. J Clin Oncol 2001, 19, 10, 17.
51. Hillner B. E., Ingle J. N., Berenson J. R. American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 18:2000;1378-1391.
52. Rubens R. D. Bone metastases - incidence and complications. Rubens RD, Mundy GR eds, Cancer and the Skeleton. 2000;Martin Dunitz, London. p. 33-42.
53. van Holten-Verzantvoort A. T., Bijvoet O. L. M., Cleton F. J. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet. ii:1987;983-985.